Skip to main content

Table 8 Probabilistic Sensitivity Analysis

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

Second-line agent add-on to Metformin Average Total Average Incremental
Costs Life Years Gained Costs Life Years Gained ICER
Sulfonylurea $7004 (±316.52) 11.93 (±0.07)    
Dipeptidyl peptidase-4 inhibitor $18790 (±1008.70) 12.52 (±0.07) $ 11786 (±976.92) 0.59 (±0.02) $19980